| Dapagliflozin (n = 40) | Sitagliptin (n = 40) | p valueb | ||||||
---|---|---|---|---|---|---|---|---|---|
Pre treatment | Post treatment | % change | p valuea | Pre treatment | Post treatment | % change | p valuea | ||
Total-C (mg/dL) | 193.5 ± 36.6 | 198.4 ± 45.9 | 2.5 | 0.863 | 192.5 ± 58.2 | 195.5 ± 38.9 | 1.6 | 0.720 | 0.102 |
TG (mg/dL) | 152.6 ± 63.7 | 133.7 ± 75.8 | −12.4 | 0.145 | 150.2 ± 85.2 | 144.6 ± 87.2 | −3.7 | 0.245 | 0.928 |
HDL-C (mg/dL) | 48.4 ± 11.1 | 53.5 ± 13.0 | 10.5 | <0.001* | 50.3 ± 9.25 | 50.3 ± 11.1 | 0 | 0.948 | 0.003* |
LDL-C (mg/dL) | 118.2 ± 32.1 | 118.8 ± 39.7 | 0.5 | 0.875 | 120.2 ± 35.1 | 114.7 ± 33.1 | −4.6 | 0.257 | 0.323 |
Non HDL-C (mg/dL) | 145.1 ± 36.0 | 144.9 ± 439 | −0.1 | 0.947 | 142.2 ± 57.3 | 145.1 ± 38.4 | 2.9 | 0.717 | 0.328 |
Apo AI (mg/dL) | 133.5 ± 21.6 | 143.5 ± 22.6 | 7.5 | 0.002* | 134.9 ± 25.2 | 128.8 ± 30.7 | −4.5 | 0.135 | 0.002* |
Apo AII (mg/dL) | 29.7 ± 4.5 | 30.9 ± 5.0 | 4.0 | 0.022* | 30.5 ± 7.2 | 30.5 ± 7.2 | 0 | 0.945 | 0.148 |
Apo B (mg/dL) | 100.1 ± 24.5 | 100.8 ± 28.1 | 0.7 | 0.777 | 102.3 ± 27.7 | 97.4 ± 26.5 | −4.8 | 0.123 | 0.131 |
Apo CII (mg/dL) | 4.8 ± 1.7 | 4.9 ± 2.2 | 2.1 | 0.362 | 5.4 ± 2.8 | 5.1 ± 2.6 | −5.6 | 0.197 | 0.105 |
Apo CIII (mg/dL) | 10.5 ± 3.2 | 11.4 ± 4.3 | 8.6 | 0.021* | 10.1 ± 4.5 | 9.6 ± 4.0 | −5.0 | 0.335 | 0.028* |
Apo E (mg/dL) | 4.4 ± 1.2 | 4.4 ± 1.5 | 0 | 0.530 | 4.3 ± 1.5 | 4.1 ± 1.0 | −4.7 | 0.296 | 0.216 |
RLP-C (mg/dL) | 6.8 ± 4.3 | 6.4 ± 5.1 | −5.9 | 0.620 | 6.9 ± 8.0 | 6.1 ± 5.7 | −11.6 | 0.303 | 0.750 |
HDL2-C (mg/dL) | 26.1 ± 8.2 | 30.8 ± 10.8 | 18.0 | <0.001* | 26.6 ± 7.9 | 27.5 ± 8.4 | 3.4 | 0.334 | 0.013* |
HDL3-C (mg/dL) | 22.2 ± 3.9 | 22.7 ± 5.0 | 2.3 | 0.527 | 23.3 ± 5.2 | 22.2 ± 5.3 | −4.7 | 0.132 | 0.130 |
sd LDL-C (mg/dL) | 54.4 ± 24.6 | 43.6 ± 24.4 | −19.9 | 0.005* | 54.0 ± 22.5 | 50.4 ± 22.4 | −6.7 | 0.368 | 0.003* |
lb LDL-C (mg/dL) | 63.8 ± 27.6 | 75.1 ± 34.1 | 17.7 | 0.026* | 66.2 ± 26.3 | 64.3 ± 24.1 | −2.9 | 0.671 | 0.029* |